Business Description
Editas Medicine Inc
NAICS : 325412
SIC : 2834
ISIN : US28106W1036
Total Employee Number:
87Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.15 | |||||
Equity-to-Asset | 0.03 | |||||
Debt-to-Equity | 3.92 | |||||
Debt-to-EBITDA | -0.17 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -14.52 | |||||
Beneish M-Score | 2.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.8 | |||||
3-Year EBITDA Growth Rate | 19.4 | |||||
3-Year EPS without NRI Growth Rate | 29.7 | |||||
3-Year FCF Growth Rate | 10.9 | |||||
3-Year Book Growth Rate | -62.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.11 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -40.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90.39 | |||||
9-Day RSI | 78.52 | |||||
14-Day RSI | 69.32 | |||||
3-1 Month Momentum % | 8.02 | |||||
6-1 Month Momentum % | 36.71 | |||||
12-1 Month Momentum % | 8.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.22 | |||||
Quick Ratio | 3.22 | |||||
Cash Ratio | 3.11 | |||||
Days Sales Outstanding | 50.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.4 | |||||
Shareholder Yield % | -4.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -230.09 | |||||
Net Margin % | -281.59 | |||||
EBITDA Margin % | -258.66 | |||||
FCF Margin % | -364.63 | |||||
OCF Margin % | -363.12 | |||||
ROE % | -429.77 | |||||
ROA % | -53.84 | |||||
ROIC % | -180.38 | |||||
3-Year ROIIC % | -86.39 | |||||
ROC (Joel Greenblatt) % | -440.27 | |||||
ROCE % | -71.67 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.9 | |||||
PB Ratio | 80.89 | |||||
Price-to-Tangible-Book | 70 | |||||
EV-to-EBIT | -4.35 | |||||
EV-to-EBITDA | -4.52 | |||||
EV-to-Revenue | 11.69 | |||||
EV-to-Forward-Revenue | 28.25 | |||||
EV-to-FCF | -3.21 | |||||
Price-to-GF-Value | 1.94 | |||||
Price-to-Median-PS-Value | 0.24 | |||||
Earnings Yield (Greenblatt) % | -22.99 | |||||
FCF Yield % | -25.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Editas Medicine Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 38.693 | ||
| EPS (TTM) ($) | -1.23 | ||
| Beta | 1.3383 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | 56.2 | ||
| 14-Day RSI | 69.32 | ||
| 14-Day ATR ($) | 0.241522 | ||
| 20-Day SMA ($) | 2.81393 | ||
| 12-1 Month Momentum % | 8.43 | ||
| 52-Week Range ($) | 1.6707 - 4.53 | ||
| Shares Outstanding (Mil) | 153.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Editas Medicine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Editas Medicine Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 39 days | ||
| General meeting for 2026 | 2026-06-17 08:30 | 2.40 (-0.41%) | ||
| Guidance call for 2026 | 2026-06-04 14:00 | 2.83 (+0.71%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 2.92 (+0.00%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-12 08:00 | 2.62 (+0.73%) | ||
| Annual report for 2025 | 2026-03-09 | 1.97 (+4.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 1.97 (+4.23%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 10:30 | 2.26 (+4.15%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-02 09:10 | 2.21 (-7.75%) |
Show
Entries
Editas Medicine Inc Frequently Asked Questions
What is Editas Medicine Inc(LTS:0IFK)'s stock price today?
The current price of LTS:0IFK is $3.50. The 52 week high of LTS:0IFK is $4.53 and 52 week low is $1.67.
When is next earnings date of Editas Medicine Inc(LTS:0IFK)?
The next earnings date of Editas Medicine Inc(LTS:0IFK) is 2026-08-12 Est..
Does Editas Medicine Inc(LTS:0IFK) pay dividends? If so, how much?
Editas Medicine Inc(LTS:0IFK) does not pay dividend.
Press Release
Articles on Editas Medicine Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers